NCT04705883View on ClinicalTrials.gov

Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

November 8, 2021

Study Completion Date

December 1, 2021

Conditions
Vulvar AtrophyBreast CancerGenitourinary Syndrome of Menopause
Interventions
DRUG

Prasterone (DHEA), Micronized

Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.

Trial Locations (1)

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors
lead

Hospital Clinic of Barcelona

OTHER

NCT04705883 - Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors | Biotech Hunter | Biotech Hunter